Since 2004, Erlotinib has been a leader in the fight against pancreatic and lung cancer. This FDA-approved pharmaceutical marvel revolutionized the NSCLC treatment landscape, and also served to combat the cancerous insulin-producing cells in the pancreas. But what exactly is erlotinib? And how does it navigate the web of cancer treatment concerns? Let’s study the […]
![Erlotinib: Targeting Lung & Pancreatic Cancers 1 39](https://gympharmacy.com/wp-content/uploads/2023/09/39.jpg)